# Compare CJC-1295/Ipamorelin, Sermorelin, and Tesamorelin — LKN Peptide

> A side-by-side comparison of three Growth Hormone Axis research peptides — CJC-1295/Ipamorelin, sermorelin, and tesamorelin — across mechanism, evidence base, administration, regulatory status, and key caution.

How a fixed secretagogue combination, a minimal physiologic fragment, and an FDA-approved long-acting analogue differ in mechanism, evidence depth, and what has actually been proven.

## The short version

This page lines up [CJC-1295/Ipamorelin](/cjc1295-ipamorelin), [sermorelin](/sermorelin), and [tesamorelin](/tesamorelin) on the dimensions that matter most when reading growth-hormone-axis peptide research: mechanism, most-studied application, evidence base, administration studied, regulatory status, and the single most important caution for each. All three are studied as ways to raise the body's own growth-hormone signal rather than replace GH directly — but they differ sharply in how well-tested that idea actually is. Tesamorelin has the deepest randomized-trial base and a current FDA approval, for one narrow indication. Sermorelin has real but older regulatory history and a mix of small modern trials and editorial disagreement. CJC-1295/Ipamorelin has solid pharmacology for each half and no controlled trial of the combination itself. None of this is medical advice, and no dose is recommended here.

## The comparison matrix

| Dimension | CJC-1295 / Ipamorelin | Sermorelin | Tesamorelin |
| --- | --- | --- | --- |
| Peptide class | GHRH analogue (CJC-1295) + selective ghrelin-receptor agonist (ipamorelin), used as a combination | GHRH(1-29) — the minimal fully active fragment of natural GHRH | Modified GHRH(1-44) analogue with a DPP-IV-resistant N-terminal group |
| Most-studied in | Each component separately: GH/IGF-1 pharmacokinetics, receptor synergy [3][4][5] | Pediatric growth-hormone deficiency (historical); cognition and body composition in small modern trials [7][10] | HIV-associated lipodystrophy (abdominal fat reduction) [1][14][16] |
| Evidence base | Single-agent human/rat pharmacology + one cell-based synergy study; no blend trial [3][4][5] | Older pediatric RCTs + small modern adult trials + editorial literature [7][8][9][10][11][12] | Multiple RCTs incl. a pooled meta-analysis; FDA-approved [1][13][14][16] |
| Administration studied | Subcutaneous injection (both components) | Subcutaneous injection, once daily | Subcutaneous injection, once daily |
| Regulatory status | Not approved; research chemicals only | Previously FDA-approved (discontinued 2008, commercial reasons); compounded today | FDA-approved (2010) for a specific HIV-related indication only |
| Key caution | Fixed blend untested; mismatched component pharmacokinetics [3][4] | Anti-aging benefit not established by rigorous trial data [8] | Approval narrow; benefit reverses on discontinuation [16] |

## Peptide class

The three compounds take different structural approaches to the same target. CJC-1295 is a modified GHRH(1-29) fragment, most often paired with ipamorelin, a selective pentapeptide agonist at the ghrelin receptor GHS-R1a — two molecules acting through two separate receptors on the same pituitary cell [5]. Sermorelin is unmodified in sequence: it is simply the natural 1-29 fragment of GHRH, the shortest piece of the hormone that retains full receptor activity. Tesamorelin keeps the complete 44-residue GHRH sequence but adds a single N-terminal modification — a trans-3-hexenoic acid group — that blocks the enzyme (DPP-IV) that would otherwise rapidly break it down, extending its effective duration relative to the unmodified hormone. All three ultimately converge on the same GHRH receptor pathway, with ipamorelin adding a second, ghrelin-receptor route.

## Most-studied application

Tesamorelin's trial program is the narrowest and deepest: essentially all of its randomized-trial evidence comes from HIV-associated lipodystrophy, where it reduces visceral and hepatic fat with a consistent, statistically significant effect size across multiple trials [1][14][16]. Sermorelin's trial history is broader but thinner in modern data: its strongest evidence is decades-old pediatric growth-deficiency trials [10], with smaller, more recent studies and editorials debating adult uses like cognition and body composition [7][8][9]. CJC-1295/Ipamorelin has no dedicated trial program of its own; what is studied is each half separately — CJC-1295's GH/IGF-1 pharmacokinetics [3][4] and ipamorelin's receptor selectivity — plus one cell-based study of the two receptors working together [5].

## Evidence base

This is where the three genuinely separate. Tesamorelin has the deepest evidence: a 2026 meta-analysis pooling five RCTs [1], a dedicated pivotal trial [14], a long-term 52-week program [16], and a formal drug-safety monograph [13] — the standard expected of an approved prescription medicine. Sermorelin's evidence is real but split across two different eras: rigorous but decades-old pediatric trials [10][11][12], and a smaller, more contested modern literature, including a widely cited editorial arguing anti-aging use is 'not yet ready for prime time' [8] alongside one arguing for sermorelin's physiologic advantages [9]. CJC-1295/Ipamorelin's evidence base is the thinnest as an actual combination: solid single-agent human and rodent pharmacology [3][4], but no controlled trial of the fixed blend, and no long-term human safety data for the combination itself.

## Administration studied

All three are studied and used as subcutaneous injections. CJC-1295's DAC form is typically dosed far less frequently than ipamorelin because of its multi-day albumin-bound half-life, while ipamorelin itself clears within hours — a mismatch in timing that is part of why the fixed combination's actual exposure profile is not well characterized [3]. Sermorelin and tesamorelin are both dosed once daily by subcutaneous injection in their respective trial programs [10][14]; tesamorelin is the only one with an FDA-specified dosing regimen as part of an approved product label.

## Regulatory and approval status

Tesamorelin is the only compound here with a current FDA approval — specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy [13]. Sermorelin was FDA-approved for pediatric growth-hormone deficiency under a branded formulation that was withdrawn from the US market in 2008 for commercial, not safety, reasons; it is treated today as a long-standing Category 1 bulk substance under FDA's interim compounding policy. Neither CJC-1295 nor ipamorelin has ever held FDA approval for any human indication; both are sold only as research chemicals, and their compounding status has shifted repeatedly — added to and then removed from an interim restricted-substances category between 2023 and 2024. All three GHRH-pathway compounds are prohibited in sport under anti-doping rules.

## Key caution

Each compound carries a defining caveat. For CJC-1295/Ipamorelin it is that the fixed combination has never been tested as a blend — its two halves have mismatched pharmacokinetics, and the actual GH exposure any given protocol produces is uncharacterized [3][4]. For sermorelin it is that its popular modern anti-aging and wellness applications outpace the trial evidence, with a major editorial concluding GH-secretagogue use for aging is 'not yet ready for prime time' [8]. For tesamorelin it is that its real regulatory rigor comes with real narrowness: the approval covers one population and one condition, its benefit reaccumulates within weeks of stopping treatment, and long-term oncologic safety beyond the trial window remains an open question [16]. Reading the three together, the pattern is consistent: the compound with the deepest trial evidence also has the narrowest studied population, and the compounds studied more broadly in research-use communities carry the least rigorous trial support.

---

LKN Peptide pairs every enthusiastic finding about the growth-hormone axis with its citation and its caveat in the same breath — a research digest, not a clinic and not a supplier.